Survival Advantage With the Addition of Radiation Therapy to Chemotherapy in Early Stage Peripheral

• 作 者: Xi-MeiZhang[1]Li-QiangZhou[2]Xin-FanLiu[3]Zi-HaoYu[3]Ye-XiongLi[3]Wei-HuWang[3]JingJin[3]Shu-LianWang[3]Yue-PingLiu[3]Yong-WenSong[3]HuiFang[3]HuaRen[3]
• 机 构: Departments of Radiation Oncology, Chinese Academy of Medical Sciences (CAMS) and Peking Union Medic
• 出 处: 北京放射肿瘤学术论坛
• 发表日期: 2014年期

　　Patients with early stage peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS) have a poor prognosis, and data on early stage PTCL-NOS are lacking.This study describes the outcome in such patients in detail for the first time, to our knowledge.Thirty-five patients with early stage PTCL-NOS were included.A valuable finding from this study is that the addition of radiation therapy to doxorubicin-based chemotherapy significantly improved overall survival and progression-free survival.